This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

PiA: Prognosis Used Every Day for Patients With Operable Breast Cancer - Comparison of Invasion Factors uPA/PAI-1 With Other Prognostic Factors (PiA)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Eva Johanna Kantelhardt, Martin-Luther-Universität Halle-Wittenberg Identifier:
First received: May 3, 2012
Last updated: June 23, 2017
Last verified: June 2017
The improvement of the healing rates for breast cancer is based to an important part on the consistent use of so-called adjuvant ("supporting ") medicamentous therapies, including chemotherapy. However this success has a price due to still inaccurate knowledge of the individual risk of relapse: a high number of unnecessary therapies are applied (over-therapy!). The invasion factors uPA (plasminogen activator of the urokinase type) and PAI-1 (uPA inhibitor) were described extensively as strong and independent prognosis factors with high clinical relevance for patients with node negative breast cancer. Compared to clinical and pathological factors (further: "traditional factors ") they show better estimation of the relapse risk leading to an avoidance of redundant adjuvant chemotherapy and may thus essentially contribute to the improvement of the quality of life in these women. In this study we aim to evaluate, how large the portion of the patients with early, operable, node negative breast cancer will be, in whom, by improved low-risk identification through uPA/PAI-1, adjuvant chemotherapy can be omitted.

Breast Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: PiA Trial: a Cross-sectional, Multicenter, Consecutive Cohort Evaluating the Distribution of uPA/PAI-1 Versus St. Gallen Algorithm in >1000 Prospectively Included Patients

Resource links provided by NLM:

Further study details as provided by Eva Johanna Kantelhardt, Martin-Luther-Universität Halle-Wittenberg:

Primary Outcome Measures:
  • Event free survival [ Time Frame: 2.5 years minimum observation time ]
    All patients will be followed after a minimum observation time of 2.5 years.

Secondary Outcome Measures:
  • Overall survival [ Time Frame: 2.5 years ]
    All patients will be followed after a minimum observation time of 2.5 years

Biospecimen Retention:   Samples With DNA
Tumor specimen frozen Tumor specimen formalin fixed

Estimated Enrollment: 1000
Study Start Date: September 2009
Estimated Study Completion Date: May 2021
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with newly diagnosed, operable breast cancer without metastasis.

Inclusion Criteria:

  • newly diagnosed breast cancer
  • no metastasis detected
  • operation for breast cancer
  • female patient
  • unilateral breast cancer
  • informed consent given
  • age min. 18 yrs.

Exclusion Criteria:

  • metastasis of breast cancer
  • bilateral breast cancer
  • other cancer within the last 5yrs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01592825

Sponsors and Collaborators
Martin-Luther-Universität Halle-Wittenberg
Principal Investigator: Eva J Kantelhardt, MD Gynecology Martin Luther Univ Halle/Germany
  More Information

Responsible Party: Eva Johanna Kantelhardt, Dr. med. E. Kantelhardt, Martin-Luther-Universität Halle-Wittenberg Identifier: NCT01592825     History of Changes
Other Study ID Numbers: GYN_Halle_01
Study First Received: May 3, 2012
Last Updated: June 23, 2017

Keywords provided by Eva Johanna Kantelhardt, Martin-Luther-Universität Halle-Wittenberg:
Breast Cancer
Prognostic factor

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on August 23, 2017